We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Metabolomic Profile Predicts Type II Diabetes Risk for Normal Weight Individuals

By LabMedica International staff writers
Posted on 05 May 2022

Employing a metabolomics approach, a team of Swedish investigator identified a panel of metabolites linked to obesity and found that normal weight individuals with this metabolic profile had increased risk for Type II diabetes and all-cause mortality compared with lean individuals with a healthy metabolome. More...

The "metabolome" includes four major classes of biological molecules: lipids, proteins/amino-acids, sugars, and nucleic acids.

Obesity is a key risk factor for Type II diabetes; however, up to 20% of diabetes patients are normal weight. Therefore, investigators aimed to identify metabolite patterns that were reproducibly predictive of BMI (body mass index) and subsequently to test whether lean individuals who expressed an obese metabolome were at hidden high risk of obesity-related diseases, such as Type II diabetes.

BMI is a measure of body fat based on height and weight, which is used to evaluate if a person is underweight, of normal weight, or obese. To determine whether they could identify a BMI-linked metabolome, investigators at Lund University (Sweden) measured levels of 108 metabolites associated with Type II diabetes in plasma samples from 7,663 individuals from two Swedish and one Italian population-based cohort. Ridge regression was used to predict BMI using the metabolites.

Individuals with a predicted BMI either higher (overestimated) or lower (underestimated) than their actual BMI were characterized as outliers and further investigated for obesity-related risk factors and future risk of Type II diabetes and mortality.

The participants were divided into five groups based on the relationship between the BMI linked to weight and height and their metabolic BMI. The five groups were (1) individuals with a normal BMI based on weight, height, and metabolism; (2) overweight individuals based on weight, height, and metabolism; (3) obese individuals based on weight, height, and metabolism. (4) Individuals in this group had a normal BMI based on height and weight. Their metabolic BMI had metabolic alterations associated with obesity. (5) Individuals in this group had a metabolic BMI which was lower than their BMI based on weight and height.

Results revealed that the metabolome could predict BMI in all cohorts. The overestimated group had a BMI similar to individuals correctly predicted as normal weight, had a similar waist circumference, were not more likely to change weight over time, but had a two times higher risk of future Type II diabetes and an 80% increased risk of all-cause mortality. These associations remained after adjustments for obesity-related risk factors and lifestyle parameters.

Senior author Dr. Olle Melander, professor of internal medicine at Lund University, said, “We hope that our research will be used to identify individuals with a hidden risk of developing the disease. If we can find these individuals before the disease debuts, we would be able to initiate preventive actions. This could potentially save society a lot of money as Type II diabetes often leads to a variety of different complications.”

The study was published in the March 14, 2022, online edition of the journal Diabetes Care.

Related Links:
Lund University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Clinical Chemistry Analyzer
Envoy 500+
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Blood proteins measured years before diagnosis may signal future prostate cancer risk, including aggressive disease.(Image Credit: iStock)

Blood Proteins Reveal Signals Linked to Prostate Cancer Risk Years Before Diagnosis

Prostate cancer is the most commonly diagnosed cancer in men worldwide. While many tumors grow slowly, aggressive forms can be life-threatening, underscoring the need for earlier risk identification.... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: Beginning in 2027, Quest will provide access to the Onclarity Self-Collection Kit through clinician, health plan, and consumer-initiated testing channels, along with its patient service center network.

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection

Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.